Answers are grounded in this paper and cite their sources.
Pulmonary vascular disease and pulmonary hypertension contribute to the pathophysiology and outcomes of infants with bronchopulmonary dysplasia. Data are extremely limited regarding many aspects of pulmonary hypertension in bronchopulmonary dysplasia, including the need to learn more about its natural history and prevalence, mechanisms that cause pulmonary hypertension or contribute to progressive disease, and the relative risks and benefits of current therapeutic strategies. Although new therapies are now available for the treatment of pulmonary hypertension, their role in the clinical care of severe bronchopulmonary dysplasia, and improving long-term outcomes requires more thorough investigation.
No takes yet. Share an insight, caveat, or question.
Steven H. Abman (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: